InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.
What is special about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

MS4gUGlvbm VlcmluZyBS b2xlIGluIE hJVi9BSURT IFRyZWF0bW VudDogR2ls ZWFkIFNjaW VuY2VzIHBs YXllZCBhIG NydWNpYWwg cm9sZSBpbi B0aGUgZGV2 ZWxvcG1lbn Qgb2YgYW50 aXJldHJvdm lyYWwgZHJ1 Z3MgZm9yIH RoZSB0cmVh dG1lbnQgb2 YgSElWL0FJ RFMuIEl0cy BmaXJzdCBk cnVnLCBWaX JlYWQsIHdh cyB0aGUgZm lyc3Qgb25j ZS1kYWlseS wgc2luZ2xl LXRhYmxldC ByZWdpbWVu IGZvciBISV YgdHJlYXRt ZW50LCB3aG ljaCByZXZv bHV0aW9uaX plZCBISVYg dGhlcmFweS 48YnI+Mi4g SW5ub3ZhdG l2ZSBSZXNl YXJjaCBhbm QgRGV2ZWxv cG1lbnQ6IF RoZSBjb21w YW55IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiByZXNl YXJjaCBhbm QgZGV2ZWxv cG1lbnQgYW 5kIGhhcyBh IHRyYWNrIH JlY29yZCBv ZiBicmluZ2 luZyBpbm5v dmF0aXZlIH RoZXJhcGll cyB0byB0aG UgbWFya2V0 LiBJdCBoYX MgYSByb2J1 c3QgcGlwZW xpbmUgb2Yg ZHJ1Z3MgaW 4gdmFyaW91 cyBzdGFnZX Mgb2YgY2xp bmljYWwgZG V2ZWxvcG1l bnQsIGluY2 x1ZGluZyB0 cmVhdG1lbn RzIGZvciBj YW5jZXIsIG xpdmVyIGRp c2Vhc2VzLC BhbmQgaW5m bGFtbWF0b3 J5IGFuZCBy ZXNwaXJhdG 9yeSBjb25k aXRpb25zLj xicj4zLiBH cm91bmRicm Vha2luZyBI ZXBhdGl0aX MgQyBUcmVh dG1lbnQ6IE dpbGVhZCdz IGJyZWFrdG hyb3VnaCBk cnVnLCBTb3 ZhbGRpLCB3 YXMgdGhlIG ZpcnN0IG9y YWwgdGhlcm FweSBmb3Ig aGVwYXRpdG lzIEMgdGhh dCBvZmZlcm VkIGEgY3Vy ZSBmb3IgdG hlIGRpc2Vh c2UuIEl0IH dhcyBhbHNv IHRoZSBmYX N0ZXN0LXNl bGxpbmcgZH J1ZyBpbiBo aXN0b3J5LC ByZWFjaGlu ZyAkMTAgYm lsbGlvbiBp biBzYWxlcy B3aXRoaW4g aXRzIGZpcn N0IHllYXIg b2YgcmVsZW FzZS48YnI+ NC4gQ29tbW l0bWVudCB0 byBBY2Nlc3 MgYW5kIEFm Zm9yZGFiaW xpdHk6IFRo ZSBjb21wYW 55IGlzIGNv bW1pdHRlZC B0byBwcm92 aWRpbmcgYW NjZXNzIHRv IGl0cyBsaW ZlLXNhdmlu ZyBtZWRpY2 F0aW9ucyB0 byBwYXRpZW 50cyBpbiBu ZWVkIGFyb3 VuZCB0aGUg d29ybGQuIE l0IGhhcyBl c3RhYmxpc2 hlZCBudW1l cm91cyBwcm 9ncmFtcyB0 byBtYWtlIG l0cyBtZWRp Y2F0aW9ucy BhY2Nlc3Np YmxlIGFuZC BhZmZvcmRh YmxlLCBpbm NsdWRpbmcg cHJpY2luZy BhZ3JlZW1l bnRzIHdpdG ggdmFyaW91 cyBjb3VudH JpZXMgYW5k IGEgcGF0aW VudCBhc3Np c3RhbmNlIH Byb2dyYW0g Zm9yIHVuaW 5zdXJlZCBh bmQgdW5kZX JpbnN1cmVk IGluZGl2aW R1YWxzIGlu IHRoZSBVbm l0ZWQgU3Rh dGVzLjxicj 41LiBTdHJv bmcgRmluYW 5jaWFsIFBl cmZvcm1hbm NlOiBHaWxl YWQgU2NpZW 5jZXMgaGFz IGNvbnNpc3 RlbnRseSBk ZWxpdmVyZW Qgc3Ryb25n IGZpbmFuY2 lhbCByZXN1 bHRzLCB3aX RoIGEgc3Rl YWR5IGluY3 JlYXNlIGlu IHJldmVudW UgYW5kIGVh cm5pbmdzLi BJdHMgZmlu YW5jaWFsIH N0YWJpbGl0 eSBhbGxvd3 MgdGhlIGNv bXBhbnkgdG 8gaW52ZXN0 IGluIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudCBh bmQgZGl2ZX JzaWZ5IGl0 cyBwb3J0Zm 9saW8uPGJy PjYuIFNvY2 lhbCBSZXNw b25zaWJpbG l0eTogVGhl IGNvbXBhbn kgaXMgY29t bWl0dGVkIH RvIG1ha2lu ZyBhIHBvc2 l0aXZlIGlt cGFjdCBiZX lvbmQgaXRz IHByb2R1Y3 RzLCB3aXRo IGEgZm9jdX Mgb24gc29j aWFsIHJlc3 BvbnNpYmls aXR5IGFuZC BzdXN0YWlu YWJpbGl0eS 4gSXQgaGFz IGluaXRpYX RpdmVzIHRv IHJlZHVjZS BpdHMgZW52 aXJvbm1lbn RhbCBmb290 cHJpbnQsIH Byb21vdGUg ZGl2ZXJzaX R5IGFuZCBp bmNsdXNpdm l0eSBpbiBp dHMgd29ya2 ZvcmNlLCBh bmQgc3VwcG 9ydCBjb21t dW5pdGllcy BpbiBuZWVk Ljxicj43Li BDb3Jwb3Jh dGUgQ3VsdH VyZTogR2ls ZWFkIFNjaW VuY2VzIGlz IGtub3duIG ZvciBpdHMg aW5jbHVzaX ZlIGFuZCBz dXBwb3J0aX ZlIGNvcnBv cmF0ZSBjdW x0dXJlLCB3 aGljaCBwcm 9tb3RlcyBp bm5vdmF0aW 9uLCBjb2xs YWJvcmF0aW 9uLCBhbmQg ZW1wbG95ZW UgZGV2ZWxv cG1lbnQuIF RoZSBjb21w YW55IGhhcy BiZWVuIHJl Y29nbml6ZW Qgd2l0aCBu dW1lcm91cy Bhd2FyZHMg Zm9yIGl0cy B3b3JrcGxh Y2UgY3VsdH VyZSwgaW5j bHVkaW5nIG JlaW5nIG5h bWVkIG9uZS BvZiB0aGUg YmVzdCBwbG FjZXMgdG8g d29yayBmb3 IgTEdCVFEg ZXF1YWxpdH ku
What the company's business model?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==
Interesting facts about the company
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ†“ Discover "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free eBook!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmCBDbGFp bSB5b3VyIG ZyZWUgZUJv b2s6IDxpPi JUaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzIjwvaT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9wPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxMnB4Oy Bmb250LXNp emU6IDEzcH g7IGNvbG9y OiAjNDQ0Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IG5vdyBhbm QgZ2V0IG91 ciBmcmVlIG VCb29rIAog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGI+ VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr czwvYj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IC0tPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID E2cHg7IGZv bnQtc2l6ZT ogMTRweDsg Y29sb3I6IC M0NDQ7IGZv bnQtZmFtaW x5OiAtYXBw bGUtc3lzdG VtLCBCbGlu a01hY1N5c3 RlbUZvbnQs IFNlZ29lIF VJLCBSb2Jv dG8sIEhlbH ZldGljYSBO ZXVlLCBzYW 5zLXNlcmlm OyBsaW5lLW hlaWdodDog MS42Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBIYX ZlIHlvdSBo ZWFyZCBhYm 91dCBvdXIg c2hvcnQgPH N0cm9uZyBz dHlsZT0nZm 9udC13ZWln aHQ6IDYwMD snPkRhaWx5 IFZpZGVvIE 5ld3NsZXR0 ZXI8L3N0cm 9uZz4/CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdodH RwczovL3d3 dy5pbnNpZ2 h0ZnVsdmFs dWUuY29tL2 5ld3NsZXR0 ZXIucGhwJy B0YXJnZXQ9 J19ibGFuay cgc3R5bGU9 J2NvbG9yOi AjMDA3QkZG OyB0ZXh0LW RlY29yYXRp b246IG5vbm U7IGZvbnQt d2VpZ2h0Oi A1MDA7IG1h cmdpbi1sZW Z0OiA2cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBGaW 5kIG91dCBt b3JlCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8L2E+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgCiAg ICAgICAgCi AgICAgICAg PHNwYW4gY2 xhc3M9J2Js dXJyZWQtdG V4dCc+CiAg ICAgICAgIC AgIE1TNGdS MmxzWlcgRm tJRk5qYVdW dSBZMlZ6SU hkaGN5IEJt YjNWdVpHVm sgSUdsdUlE RTVPRCBjZ1 lua2dUV2xq IGFHRmxiQ0 JTYVcgOXla R0Z1TENCaC BJRzFsWkds allXIHdnWk c5amRHOXkg SUdaeWIyMG dUbSBWM0lG bHZjbXN1IE lGUm9aU0Jq YjIgMXdZVz U1SUhkaCBj eUJ1WVcxbF pDIEJoWm5S bGNpQjAgYU dVZ1ltbGli RyBsallXd2 diR0Z1IFpD QnZaaUJIYV cgeGxZV1Fz SUhkbyBhV0 5vSUhkaGN5 IEJyYm05M2 JpQm0gYjNJ Z2FYUnpJRy BobFlXeHBi bWNnIGNISn ZjR1Z5ZEcg bGxjeTQ4WW 5JKyBNaTRn UjJsc1pXIE ZrSUZOamFX VnUgWTJWek lHbHpJRyBF Z1ltbHZjR2 hoIGNtMWhZ MlYxZEcgbG pZV3dnWTI5 dCBjR0Z1ZV NCMGFHIEYw SUdadlkzVn ogWlhNZ2Iy NGdaRyBWMl pXeHZjR2x1 IFp5QmhibV FnWTIgOXRi V1Z5WTJsaC BiR2w2YVc1 bklIIFJvWl hKaGNHbGwg Y3lCbWIzSW diRyBsbVpT MTBhSEpsIF lYUmxibWx1 WnkgQmthWE 5sWVhObCBj eXdnZDJsMG FDIEJoSUhC aGNuUnAgWT NWc1lYSWda bSA5amRYTW diMjRnIFNF bFdMMEZKUk YgTXNJR2hs Y0dGMCBhWF JwY3lCQ0lH IEZ1WkNCRE xDQnMgYVha bGNpQmthWC BObFlYTmxj eXdnIGIyNW piMnh2WjMg a3NJR0Z1Wk NCeSBaWE53 YVhKaGRHID l5ZVNCa2FY TmwgWVhObG N5NDhZbiBJ K015NGdWR2 hsIElHTnZi WEJoYm4gbm lnSmx6SUda cCBjbk4wSU cxaGFtIDl5 SUdKeVpXRn IgZEdoeWIz Vm5hQyBCal lXMWxJR2x1 IElERTVPVF lnZDIgbDBh Q0IwYUdVZy BZWEJ3Y205 MllXIHdnYj JZZ2RHaGwg YVhJZ1NFbF dJSCBSeVpX RjBiV1Z1IG RDQmtjblZu TEMgQldhWE psWVdRcyBJ SGRvYVdOb0 lIIGRoY3lC MGFHVWcgWm 1seWMzUWdk SCBKbFlYUn RaVzUwIElI UnZJSFJoY2 0gZGxkQ0Jo YmlCbCBibn A1YldVZ1ky IEZzYkdWa0 lISmwgZG1W eWMyVWdkSC BKaGJuTmpj bWx3IGRHRn paU0IwYUcg RjBJR2x6SU dWeiBjMlZ1 ZEdsaGJDIE JtYjNJZ2RH aGwgSUhKbG NHeHBZMiBG MGFXOXVJRz ltIElIUm9a U0JJU1YgWW dkbWx5ZFhN dSBQR0p5UG pRdUlFIGx1 SURJd01URX MgSUVkcGJH VmhaQyBCVF kybGxibU5s IGN5QmhZM0 YxYVggSmxa Q0IwYUdVZy BZbWx2Y0do aGNtIDFoWT JWMWRHbGog WVd3Z1kyOX RjRyBGdWVT d2dVR2hoIG NtMWhjM05s ZEMgd2dabT l5SUNReCBN U0JpYVd4c2 FXIDl1TGlC VWFHbHogSU dGamNYVnBj MiBsMGFXOX VJR0p5IGIz Vm5hSFFnUj IgbHNaV0Zr SUhSbyBaU0 JpYkc5amEy IEoxYzNSbG NpQmsgY25W bkxDQlRiMy BaaGJHUnBM Q0IzIGFHbG phQ0J5Wlgg WnZiSFYwYV c5dSBhWHBs WkNCMGFHIF VnZEhKbFlY UnQgWlc1ME lHWnZjaSBC b1pYQmhkR2 wwIGFYTWdR eTQ4WW4gSS tOUzRnUjJs cyBaV0ZrSU ZOamFXIFZ1 WTJWeklHaG ggY3lCaElI TjBjbSA5dV p5QmpiMjF0 IGFYUnRaVz UwSUggUnZJ R052Y25Cdi BjbUYwWlNC emIyIE5wWV d3Z2NtVnog Y0c5dWMybG lhVyB4cGRI a3VJRlJvIF pTQmpiMjF3 WVcgNTVJR2 hoY3lCayBa WFpsYkc5d1 pXIFFnWVc0 Z1lXTmogWl hOeklIQnli MiBkeVlXMG dkRzhnIGNI SnZkbWxrWl MgQnBkSE1n YldWayBhV0 5oZEdsdmJu IE1nZEc4Z2 JHOTMgTFds dVkyOXRaUy BCamIzVnVk SEpwIFpYTW dZWFFnWkcg bHpZMjkxYm 5SbCBaQ0J3 Y21salpYIE 1zSUdGdVpD QmggYkhOdk lHaGhjeSBC d2NtOW5jbU Z0IGN5QjBi eUJ6ZFggQn diM0owSUdO diBiVzExYm 1sMGVTIEJo Ym1RZ1pXUj EgWTJGMGFX OXVZVyB3Z2 FXNXBkR2xo IGRHbDJaWE 11UEcgSnlQ all1SUVsdS BJREl3TWpB c0lFIGRwYk dWaFpDQlQg WTJsbGJtTm xjeSBCdFlX UmxJR2hsIF lXUnNhVzVs Y3kgQjNhWF JvSUdsMCBj eUJsZUhCbG NtIGx0Wlc1 MFlXd2cgWk hKMVp5d2dj bSBWdFpHVn phWFpwIGNp d2dkMmhwWT IgZ2djMmh2 ZDJWayBJSE J5YjIxcGMy IGx1WnlCeV pYTjEgYkhS eklHbHVJSC BSeVpXRjBh VzVuIElFTl BWa2xFTFQg RTVJSEJoZE dsbCBiblJ6 TGlCVWFHIF VnWkhKMVp5 QnkgWldObG FYWmxaQyBC bGJXVnlaMl Z1IFkza2dk WE5sSUcgRj FkR2h2Y21s NiBZWFJwYj I0Z1puIEp2 YlNCMGFHVW cgUmtSQklH RnVaQyBCb1 lYTWdjMmx1 IFkyVWdZbV ZsYmkgQmth WE4wY21saS BkWFJsWkNC aGNtIDkxYm 1RZ2RHaGwg SUhkdmNteG tMaiB4aWNq NDNMaUJIIG FXeGxZV1Fn VTIgTnBaVz VqWlhNZyBh R0Z6SUdFZ1 pHIGwyWlhK elpTQjMgYj NKclptOXlZ MiBVc0lIZH BkR2dnIFpX MXdiRzk1Wl cgVnpJR1p5 YjIwZyBiM1 psY2lBMk5T IEJqYjNWdW RISnAgWlhN Z1lXNWtJRy BFZ2JHVmha R1Z5IGMyaH BjQ0IwWlcg RnRJRzFoWk dVZyBkWEFn YjJZZ05EIG NsSUhkdmJX VnUgTGp4aW NqNDRMaSBC VWFHVWdZMj l0IGNHRnVl U0JvWVggTW dZU0J6ZEhK diBibWNnWj J4dlltIEZz SUhCeVpYTm wgYm1ObExD QjNhWCBSb0 lHOXdaWEpo IGRHbHZibk 1nYVcgNGdU bTl5ZEdnZy BRVzFsY21s allTIHdnUl hWeWIzQmwg TENCS1lYQm hiaSB3Z1lX NWtJRUZ6IG FXRWdVR0Zq YVcgWnBZeT Q4WW5JKyBP UzRnUjJsc1 pXIEZrSUZO amFXVnUgWT JWeklHaGhj eSBCaVpXVn VJRzVoIGJX VmtJRzl1Wl MgQnZaaUIw YUdVZyBWMj l5YkdUaWdK IGx6SUUxdm MzUWcgUVdS dGFYSmxaQy BCRGIyMXdZ VzVwIFpYTW dZbmtnUm0g OXlkSFZ1Wl NCTiBZV2Ro ZW1sdVpTIE JtYjNJZ1pt OTEgY2lCam IyNXpaVyBO MWRHbDJaU0 I1IFpXRnlj eUFvTWogQX hOeTB5TURJ dyBLUzQ4WW 5JK01UIEF1 SUVkcGJHVm ggWkNCVFky bGxibSBObG N5QnBjeUJq IGIyMXRhWF IwWlcgUWdk RzhnYzNWei BkR0ZwYm1G aWFXIHhwZE hrZ1lXNWsg SUdoaGN5Qn paWCBRZ2RH RnlaMlYwIG N5QjBieUJ5 WlcgUjFZMl VnZEdobCBh WElnWlc1Mm FYIEp2Ym0x bGJuUmggYk NCcGJYQmhZ MyBRc0lHbH VZMngxIFpH bHVaeUJoSU cgZHZZV3dn ZEc4ZyBjMj kxY21ObElE IEV3TUNVZ2 NtVnUgWlhk aFlteGxJRy BWc1pXTjBj bWxqIGFYUj VJR0o1SUQg SXdNakFnWV c1ayBJSEps WkhWalpTIE JuY21WbGJt aHYgZFhObE lHZGhjeSBC bGJXbHpjMm x2IGJuTWdZ bmtnTWogVW xJR0o1SURJ dyBNakl1Ci AgICAgICAg PC9zcGFuPg ogICAgICAg IAogICAgIC AgIA==
See Company Q&A
Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal